The risk of constructing any new managed access process within the current application of HTA policy risks the creation of another rarely used process that will not benefit the people a public health program is designed to serve.
No need for reviews or new processes, just lead and direct them to do it
June 26, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Queensland to host AusBiotech International Conference and sector leadership strengthened with director re-election
October 24, 2025 - - Australian Biotech -
David Henderson to Lead Takeda’s Specialty Franchise in Oceania
October 24, 2025 - - Latest News -
New Zealand identified as a ‘major outlier’ in OECD medicines investment
October 24, 2025 - - BioPharma -
A perspective that rightly belongs in a time capsule from the 1990s
October 23, 2025 - - Latest News -
Global focus intensifies as AusBiotech strengthens trade, partnerships and international engagement
October 23, 2025 - - Australian Biotech -
Queensland resources sector backs prevention-first health push to boost workforce productivity
October 23, 2025 - - Latest News -
Omico appoints Richard Vines as new Chair as it strengthens national precision oncology agenda
October 23, 2025 - - Latest News
